Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 211 to 220 of 241 total matches.

Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
upper respiratory tract infection (22%), decreased appetite (19%), mood changes (11%), insomnia (9 ...
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):157-9 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
= direct oral anticoagulant; NSAIDs = nonsteroidal anti-inflammatory drugs; UTI = urinary tract infection ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction

Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
infection. A boxed warning in its label states that zuranolone can impair the ability to drive or engage ...
The FDA has approved the oral GABAA receptor modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression (PPD). Zuranolone is the second drug to be approved for this indication; brexanolone (Zulresso), another GABAA receptor modulator, was approved for IV treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3   doi:10.58347/tml.2023.1692a |  Show IntroductionHide Introduction

A New RSV Vaccine (mResvia) for Adults ≥60 Years Old

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
months with Abrysvo).6,7 RSV DISEASE — RSV typically causes a mild upper respiratory tract infection ...
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo, are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-8   doi:10.58347/tml.2024.1713d |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
as with dopamine agonists iInhaled levodopa can cause cough, upper respiratory infection, and sputum ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction

Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
of lonapegsomatropin in the heiGHt trial (occurring in >5% of patients) were viral infection, pyrexia, cough, nausea ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children ≥1 year old who weigh ≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):20-2 |  Show IntroductionHide Introduction

Inclisiran (Leqvio) for LDL-Cholesterol Lowering

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
reactions (8%), arthralgia (5%), urinary tract infections (4%), diarrhea (4%), bronchitis (4%), extremity ...
The FDA has approved inclisiran (Leqvio – Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated statin therapy for subcutaneous (SC) treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Inclisiran is the first FDA-approved PCSK9-directed siRNA therapeutic agent.
Med Lett Drugs Ther. 2022 Mar 21;64(1646):43-5 |  Show IntroductionHide Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
or periocular infections or active intraocular inflammation. PREGNANCY AND LACTATION — Based on its mechanism ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 |  Show IntroductionHide Introduction

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
and/or oropharyngeal fungal infections and increased intraocular pressure have also been reported. Use of intranasal ...
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4   doi:10.58347/tml.2023.1668c |  Show IntroductionHide Introduction

Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
congestion, pharyngitis, rhinitis, respiratory tract infection, gastroenteritis, and otitis media ...
The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta2-agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients ≥18 years old with asthma. Airsupra is the first combination of a SABA and an ICS to become available in the US. It is not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3   doi:10.58347/tml.2024.1698a |  Show IntroductionHide Introduction